On Jun. 23, 2020, Mateon Therapeutics announced it had selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101. This study is designed to evaluate the safety, tolerability, and effectiveness of OT-101 when used in combination with standard of care (SoC) in hospitalized COVID-19 patients.

OT-101 is a wide spectrum anti-viral agent with demonstrated activity against SARS-CoV-2 in the nanomolar range comparable to remdesivir, however, with higher safety index. By targeting the host protein, TGF-, OT-101 avoids resistance mutations which could render vaccine and/or therapeutics against viral protein(s) ineffective.